Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.59 |
| ▸ | CA6 | P23280 | 3/20 | 0.59 |
| ▸ | CA5A | P35218 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338732 | 0.83 | CA1 (0.50) | SMN1; SMN2CA12CA1CA2CA3 | |
| SCHEMBL196630 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA2CA3 | |
| SCHEMBL2936178 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL12989147 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA2VCAM1ALDH1A1 | |
| SCHEMBL11135901 | 0.78 | TSHR (0.50) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL21646275 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA2CA3 | |
| SCHEMBL11153175 | 0.78 | CA1 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL4613713 | 0.77 | APOBEC3G (0.54) | SMN1; SMN2VCAM1ALDH1A1MEN1KMT2A | |
| SCHEMBL196979 | 0.77 | CA12 (0.69) | SMN1; SMN2CA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL28541249 | 0.76 | APOBEC3G (0.52) | SMN1; SMN2VCAM1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | SMN1; SMN2 148/4885CA12 2178/4885CA1 573/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | SMN1; SMN2 148/4885CA12 2178/4885CA1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.